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Abstract
The article relates the ability of the malaria parasite Plasmodium falciparum to avoid a protective immune response, and
to induce pathological changes, to the properties of specific parasite molecules. Cytoadherence and rosetting are important
features of cerebral malaria and involve proteins located on the surface of the infected red blood cell. Proinflammatory
 .cytokines, particularly tumour necrosis factor TNF , play a role in protective immunity and in inducing pathology.
Glycophosphatidyl inositol membrane anchors of parasite proteins possess insulin like activity and induce TNF synthesis.
People subject to repeated infections in malaria endemic areas rarely develop complete or sterile immunity to malaria. They
frequently carry small numbers of parasites in the blood, with little symptoms of the disease, illustrating a phenomenon
termed semi-immunity. The basis for semi-immunity is incompletely understood. Malaria parasites are susceptible to several
immunological effector mechanisms. The presence of extensive repetitive regions is a feature of many P. falciparum
proteins. Available evidence suggests that the structural characteristics of the repeats and their location on the surface of
 .parasite proteins promote immunogenicity. The repeats may help the parasite evade host immunity by i exhibiting
 .  .sequence polymorphism, ii preventing the normal affinity and isotype maturation of an immune response, iii functioning
 .  .possibly as B cell superantigens, iv generating predominantly thymus independent antibody responses, and v acting as a
sink for binding protective antibodies. Sequence diversity in non-repetitive regions and antigenic variation in parasite
molecules located on the surface of infected red blood cells also play a role in immune evasion. Some sequence homologies
between parasite and human proteins may be due to molecular mimicry. Homologies in other instances can cause
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endothelial leukocyte adhesion molecule; FIRA, falciparum interspersed repeat antigen; GBP, glycophorin binding protein; GPI,
glycophosphatidyl inositol; HMS, hyperreactive malarious splenomegaly syndrome; ICAM, intercellular adhesion molecule; IL, inter-
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associated molecule; LSA, liver stage antigen; MHC, major histocompatibility complex; MSA, merozoite surface antigen; Pf ,
Plasmodium falciparum; Pf EMP, Plasmodium falciparum erythrocyte membrane protein; P˝, Plasmodium vivax; rbc, red blood cell;
RAP, rhoptry associated protein; RESA, ring erythrocyte surface antigen; S-antigen, heat stable polymorphic antigen; SERA, serine rich
antigen; SICA, schizont infected cell agglutinin; TM, transmembrane; TNF, tumour necrosis factor; VCAM, vascular cell adhesion
molecule
) Corresponding author. E-mail: ranjan@ifs.ac.lk
0925-4439r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
 .PII S0925-4439 97 00078-1
( )R. RamasamyrBiochimica et Biophysica Acta 1406 1998 10–27 11
autoimmune responses. The immune evasion mechanisms of the parasite need to be considered in developing vaccines.
Protective immunity and pathology may be delicately balanced in malaria. q 1998 Elsevier Science B.V.
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1. Introduction
Malaria is a re-emerging disease that produces
3=108–5=108 new infections and 1.5=106–2.7
6 w x=10 deaths every year 1 . Much of the mortality
occurs among children in sub-Sahara countries, with
4% of deaths among infants and 25% among 1–4
year old children in The Gambia being attributed to
w xmalaria 2 . The incidence is increasing in many
tropical underdeveloped countries because of resis-
tance of the parasite to common drugs, insecticide
resistance in the mosquito vector, the effects of civil
strife and organisational constraints. About half the
 .malaria is caused by Plasmodium falciparum Pf
and the balance by the three other species that infect
 .man viz. P. ˝i˝ax P˝ , P. malariae and P. o˝ale.
Pf causes more deaths and has been more extensively
studied because continuous in vitro culture of the
w xasexual blood stages is possible 3 . This review
therefore focuses on Pf malaria and reference is
made to the other species only where relevant.
2. Life cycle of the parasite
Sporozoites are the infective forms of the parasite
injected into the peripheral circulation when a Plas-
modium-infected female Anopheles mosquito takes a
bloodmeal. They travel through the bloodstream in-
vading hepatocytes within 1 h of inoculation and
undergo asexual schizogony to form merozoites. A
dormant liver form of the parasite known as the
hypnozoite is responsible for characteristic relapses
seen in P˝ and P. o˝ale infections. The hypnozoite
is absent in the other two species of human malaria
parasites. The rupture of infected liver cells releases
merozoites into the bloodstream. These invade red
 . blood cells rbc to produce ring stage parasites so
termed because of the signet ring like appearance
.when stained with Giemsa . The intracellular para-
sites are located within a parasitophorous vacuole
formed during the invasion process. Rings synthesise
proteases to degrade haemoglobin into amino acids.
These and other nutrients obtained from the host
enable the parasite to grow in 15–18 h into mature
trophozoites. The trophozoite then undergoes schizo-
gony to yield about 16 merozoites that are released
by the rupture of the rbc membrane. The merozoites
rapidly invade fresh rbc to continue the asexual blood
stage cycle. An asexual rbc cycle takes 48 h in Pf
and P˝. Some invading haploid merozoites develop
into male and female gametocytes within the rbc.
Gametocytes undergo gametogenesis in the mosquito
midgut following ingestion. Fertilisation produces a
diploid zygote that undergoes meiosis and differenti-
ates into a motile ookinete. The ookinete traverses the
midgut epithelium to lodge on the haemocoele side
where it develops into an oocyst. Sporozoites pro-
duced in the oocyst then migrate to the salivary gland
of the mosquito to continue the infection cycle Fig.
.1 .
3. Pathology of malaria
Much of the pathology of malaria is caused by the
w xasexual blood stages 4 . Fever due to falciparum
malaria occurs initially at 48 h intervals and lasts for
a few hours. Nausea, headache and chills accompany
the fever. The fever follows shortly after the rupture
 .of infected rbcs irbcs , a process that is relatively
synchronous at the initial stages of an infection. A
rise in serum levels of tumour necrosis factor a
 .TNFa in P˝ infections precedes fever by about
w x30 min 5 . Anti-TNFa antibody reduces fever in
w xGambian children during Pf infections 6 . It is
likely therefore that the release of parasite proteins
and other components that occur during schizogony
 .Section 4 stimulates TNFa production by T cells
and macrophages. TNFa , in turn, induces the release
 .of interleukin-1 IL-1 , the endogenous pyrogen from
macrophages and fibroblasts. Clinical complications
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Fig. 1. Life cycle of a malaria parasite.
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of Pf malaria occur particularly in non-immune adults
and children who remain untreated for several days
after the onset of fever. The most serious, and fre-
quently fatal, complication is cerebral malaria. In
severe cases this is associated with deep coma and
generalised convulsions. Obstruction of cerebral
venules and capillaries with trophozoites and sch-
izonts is a characteristic histopathological finding in
cerebral malaria. Mature Pf irbc specifically adhere
w xto endothelial cells 7 . P˝ on the other hand does not
adhere nor cause cerebral malaria. Endothelial sur-
face molecules reportedly mediating this cytoadher-
ence include a platelet derived glycoprotein throm-
w xbospondin 8 , intercellular adhesion molecule 1 or
w x w xICAM-1 9 , CD36 10 , E-selectin or endothelial
 .leukocyte adhesion molecule 1 ELAM-1 and vascu-
w xlar cell adhesion molecule1 or VCAM-1 11 , and
w xchondroitin sulphate A 12,13 . The corresponding
ligands on irbc surface are a family of 200–300 kDa
parasite proteins termed the Pf erythrocyte mem-
brane protein-1 or Pf EMP-1. These are coded for by
w x50–150 ˝ar genes 14–16 . The ˝ar genes may
account for as much as 2–6% of the haploid genome
w x15 . Modifications to the rbc anion transporter band
3 glycoprotein, involving limited proteolysis, occur in
w xmature Pf irbc 17,18 . A peptide that is only ex-
posed on the altered band 3, composed of residues
546–553 of the human protein termed Pfalhesin,
reportedly binds specifically to CD36 and therefore
w xcan contribute to cytoadherence of irbc 19 . Knob-
like protrusions of the rbc membrane with deposition
of electron dense material beneath the membrane are
seen in electron micrographs of mature asexual stages
of Pf. The knobs are frequently observed as the
attachment points of irbc to vascular endothelium in
brain autopsy sections from cerebral malaria patients
w x20 . At least two parasite derived proteins, a knob
w xassociated histidine rich protein or KAHRP 21 and
w xa 315 kDa Pf EMP3 22 , are deposited in the knobs
beneath the rbc membrane. These probably interact
with the rbc cytoskeleton. Pf EMP-1 is anchored in
the knobs by a transmembrane segment but contains
w xan extracellular region that binds antibodies 14 .
While the knob protrusions are needed for strong
cytoadherence and consequent microcirculatory ob-
w xstruction 23 , strains of parasites that do not form
knobs are also able to cytoadhere albeit more weakly
w x24 .
Histopathological observations suggest that the
binding of one or more uninfected rbc to irbc, a
w xphenomenon termed rosetting 25 , is also characteris-
w xtic of irbc sequestered in the microvasculature 20 .
Rosetting may be mediated by polymorphic 22–
28 kDa proteins termed rosettins found on the irbc
surface, with CD36 and A and B blood group sub-
w xstances on uninfected rbc serving as receptors 25 . It
has also been argued that rosetting may involve the
binding of C3b complement component on the irbc
with the corresponding CR1 receptor on uninfected
w xrbc 26 . More recently it has been reported that
PfEMP-1 on irbc binding to CR1 on uninfected rbc is
responsible for rosetting and that an allele of CR1
that demonstrates reduced affinity for PfEMP-1 is
w xcommon in Africa 27 . Fibrillar material containing
IgM or IgG and IgM are seen at the points of contact
between irbc and uninfected rbc or endothelial cells
but the significance of this phenomenon is not fully
w xunderstood 28 . In a quantitative ultrastructural study
of sequestration, the proportion of irbc and the tight-
ness of packing of the cells in different tissues fol-
lowed the order, brain)heart) liver, lungs and kid-
w xney))blood 20 .
Severe liver failure, circulatory collapse, acidosis,
hypoglycaemia, anaemia, hyperpyrexia, acute pul-
monary oedema and renal failure are other common
clinical complications observed in untreated cases of
acute falciparum malaria. Falciparum malaria is also
a major cause of maternal death, abortion, stillbirth,
premature delivery and low birthweight in endemic
areas. The placenta is a preferred site for sequestra-
tion of irbc and a sub-population of the mature forms
of Pf that adhere to chondroitin sulphate A in prefer-
w xence to CD36 can be found in infected placenta 29 .
The increased susceptibility of pregnant women to
malaria and the associated clinical complications may
be due partly to this phenomenon.
Persons living in malaria endemic areas are often
subject to repeated malaria infections and may de-
velop chronic P˝ infections. Such individuals often
suffer from what is termed the hyperreactive malari-
ous splenomegaly or HMS syndrome, which is char-
acterised by persistent moderate or marked enlarge-
w xment of the spleen 30 . This is accompanied by very
high serum IgM levels, high antibody levels to para-
site antigens, lymphocyte infiltration of hepatic sinu-
soids and liver enlargement, chronic anaemia and
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pancytopenia. Susceptibility to secondary infections
is increased in persons with HMS and this contributes
to morbidity and mortality. The human spleen has an
important role in immunity to malaria. Cytoadherence
is believed to have been evolved by the parasite for
avoiding the circulation of trophozoites and schizonts
through the reticular cellrfibre filtration beds of the
spleen, where they can be trapped and destroyed by
the combined action of T cell derived cytokines and
phagocytic cells. Trapping and destruction of mature
iRBC in the spleen may be caused also by the
inability of these cells to squeeze past the endothelial
cells of the venous sinuses due to a decreased de-
w xformability of the rbc membrane 31 . Ring stages of
Pf do not adhere and are capable of recirculating
through the spleen. Therefore Giemsa stained blood
smears of Pf patients show mainly rings while smears
from P˝ patients show mature stages besides rings.
4. A central role for TNF in malaria pathology
and its induction by parasite molecules and IgE
immune complexes
The importance of excessive production of TNF
and other cytokines in causing malaria pathology was
w xrecognised several years ago 32 . TNFa and TNFb
are synthesised by macrophages and activated T
helper cells of the T subset. They cause the produc-h1
tion of IL-1 by macrophages and fibroblasts which is
in turn responsible for the characteristic malaria fever
and the induction of IL-6 and acute phase proteins.
 .Interferon-gamma IFNg upregulates the expression
w xof TNF receptors on a variety of cells 33 , and its
release by activated T cells may potentiate theh1
action of TNF in malaria. The expression of ICAM-1
on endothelial cells and its ligand LFA-1 lympho-
.cyte function associated molecule 1 on leukocytes is
increased by TNF and this is directly related to the
w xincidence of cerebral malaria in a mouse model 34 .
One of the two alleles of the TNFa promoter region,
associated with increased inducible and constitutive
TNFa transcription, is significantly related to the
susceptibility to cerebral malaria in Gambian children
w x35 . IL-10 produced by T cells downregulatesh2
w xTNFa synthesis in falciparum malaria 36 . The ready
activation of memory T cells producing IL-10 mayh2
partly be the reason for the diminished malaria symp-
toms exhibited by many adults living in endemic
areas.
Besides enhancing the sequestration of irbc in the
brain microvasculature, increased TNF levels in
malaria induces nitric oxide synthesis in endothelial
and smooth muscle cells of the blood vessels. It has
been suggested that nitric oxide produced in this way
may diffuse into adjacent brain tissue and contribute
to cerebral malaria and the other neurological changes
w xobserved in malaria 37 .
The induction of TNF production in malaria is
related to the release of parasite material during
w xschizont rupture 5,6 . This material was shown to be
heat stable and a phospholipid containing phos-
w xphatidyl inositol 38 . The active moiety has since
 .been reported to be a glycophosphatidyl inositol GPI
w xmoiety that anchors many membrane proteins 39 .
GPI anchors are present in the 185–200 kDa and
45 kDa merozoite surface antigens termed MSA-1
w x w x40,44 and MSA-2 respectively 41–44 , and a
76 kDa protease that is activated by the cleavage of
the protein from the membrane anchor by a parasite-
derived phosphatidyl inositol-specific phospholipase
w xC 45 . A number of other parasite proteins also
incorporate radiolabelled myristic acid into a putative
GPI moiety from which the label can be cleaved by a
Bacillus cereus phosphatidyl inositol-specific phos-
w xpholipase C 44 .
GPI attached to Pf merozoite surface proteins and
purified GPI moieties can induce TNF and IL-1
w xproduction in macrophages 46 . They also produce a
marked increase in triglyceride synthesis and glucose
oxidation in isolated adipocytes, and a prolonged,
TNF independent drop in blood glucose levels in
w xmice 46 . Thus the purified GPI moieties appear to
have strong insulin-mimetic effects that may be me-
diated through interference with normal host cell
signalling pathways. Parasite material released during
schizont rupture probably contains GPI precursors,
protein associated GPI and free GPI produced by the
action of phospholipase C. All these molecules may
be involved in producing the described changes in the
host.
Natural a1-3 galactosyl antibodies present in man
and old world primates are reported to produce com-
plement mediated damage to merozoites and thereby
w xconfer a degree of protection against Pf malaria 47 .
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Pf does not synthesise N-linked oligosaccharides
w x44,48 but does synthesise O-linked oligosaccharides
w x w x49 and GPI anchors for membrane proteins 44,50 .
While there is one report that a1-3 galactosyl residues
are absent in the GPI anchors of MSA-1 and MSA-2
w x50 , this needs to be confirmed in view of the
observation that parasite glycolipids incorporate
w xgalactose 51 . Therefore the possibility that natural
anti-a1-3 galactosyl antibodies also confer protection
against malaria pathology by reacting with GPI moi-
eties requires further exploration. In this context it is
notable that antibodies to parasite molecules inducing
w xTNF are found in malaria patients 52 and semi-im-
 w x.mune Africans reported in Ref. 53 . This parallels
elevations in anti-a1-3 galactosyl antibodies seen in
w xmalaria patients and semi-immune populations 54 .
More recently it has been reported that elevated
blood IgE levels, comprising both non-specific and
anti-malarial IgE, seen in persons living in endemic
areas and in malaria patients are also responsible for
w xoverproducing TNF in malaria 55 . The proposed
mechanism is the stimulation of TNF secretion by
antigen–IgE immune complexes binding to the low
affinity FceRII receptor or CD23 on monocytermac-
w xrophages 55 .
Despite its central role in malaria pathology, the
normal function of TNF in controlling parasite growth
should be kept in mind. Thus TNF enhances neu-
trophil and monocytermacrophage mediated phago-
w xcytosis and killing of asexual blood stages 56,57
w xand hepatic stages of Pf 58 . The fever produced as
a result of TNF release may also help limit parasite
w xgrowth 59 .
5. Autoantibodies in malaria
Autoantibodies have been reported in malaria
w xagainst single-stranded DNA 60,61 , rbc poly-
w x w xpeptides 62 , cryptic rbc carbohydrate epitopes 63
w xand a variety of other tissues 64 . Many house
keeping genes in the malaria parasite are homologous
to the corresponding human genes. Sequence ho-
mologies may be expected to produce autoantibodies
through bypassing T cell tolerance. This probably is
the cause of the observed production of autoantibod-
w xies to the heat shock protein hsp70 in malaria 65 .
There is extensive sequence homology between the
w xparasite and human hsp70 65 . At a different level,
antibodies present in acute malaria patients that react
w xwith intermediate filaments of the cytoskeleton 66 ,
may be produced against cross-reactive epitopes on
w xthe Pf MSA-1 protein 67 . There is no evidence yet
to show that the rbc directed autoantibodies are wholly
responsible for the severe anaemia seen malaria,
which may be caused more by the rapid rbc turnover
due parasitisation and erythropoiesis dysfunction in
 w x.the marrow reported in Ref. 68 . Similarly other
autoantibodies have not yet been related to any spe-
cific pathological manifestations of malaria. This is
an important area that requires more investigation.
6. Immunity to malaria
A single infection with a virus in many instances is
able to produce solid immunity to reinfection for life.
Smallpox was therefore eradicable. It is also possible
to immunise against specific strains of viruses, e.g.
the influenza virus, that demonstrate limited changes
in the antigenicity of surface located molecules. Simi-
larly, immunisation against bacterial toxins, eg.
tetanus, or bacterial surface antigens, eg. from
Meningococcus, can generate long-term immunity
against infection. The situation regarding a protozoan
parasite such as Plasmodium is less clear. Studies on
individuals living in an area of continuous malaria
transmission in Liberia show that the density of Pf in
blood peaks between the ages of 6 months and 2
years and decreases after that with increasing age
w x69 . The incidence of malaria as assessed by stained
blood smears also peaks at about this age, but then
declines less sharply than parasite density with in-
creasing age. However malaria morbidity, measured
in terms of the mean body temperature produced by
any given density of Pf parasites in the blood,
w xdeclines with age 70 . The incidence of cerebral
malaria and malaria-related deaths reaches a peak at
w xage 4 year in The Gambia 70 . These and other
earlier observations are frequently interpreted as evi-
dence of a slow acquisition of immunity against
malaria because of continuous or repeated exposure
to the parasite. However studies on non-immune
migrants to Irian Jaya and syphilitic patients who
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underwent malaria therapy raise the alternate possi-
bility that adults intrinsically acquire immunity more
rapidly than children and that significant immunity
may be developed even after one or few malaria
w xinfections 71 . It is clear however that immunity to
malaria is never complete or sterilising in the sense
that parasites are not totally eliminated from the
circulation in many adults exposed to repeated infec-
tions in endemic areas. Rather the immunity appears
to reduce parasite growth and disease symptoms in
such persons, who may therefore be termed to be
semi-immune to malaria. The differences between the
immunity developed to viral and bacterial diseases
and malaria may be attributed to the more complex
life cycle and genome of Plasmodium. Consequently
Plasmodium presents many more antigens to the
immune system and demonstrates sophisticated
mechanisms of immune evasion. The ability of the
parasite to escape protective host immune responses
tends to produce, in the absence of drug treatment,
either chronic infections in the long term with mini-
 .mal clinical symptoms semi-immunity , or over-
whelming infections that cause severe disease and
death. However several immunological effector
mechanisms operative against the malaria parasite
have been elucidated and these are summarised be-
low in Table 1.
7. Repetitive sequences of parasite proteins in
immune evasion
7.1. Pre˝alence of repetiti˝e sequences in Pf proteins
Many Pf antigens characterised to date contain
regions composed of tandemly repeated sequences
termed repeats. Tandem repeats, although found in
collagen, serum complement proteins and associated
w xmembrane receptors, e.g. CR2 or CD21 97 , are
relatively uncommon in human proteins. Because of
the stability of epitopes in repeats and the presence of
multimeric epitopes, it can be argued that the screen-
ing of Pf expression DNA libraries with immune
w xhuman sera 98 selects for genes coding for antigens
containing repeats. This may also be a consequence
of a biased representation of antibodies directed
against repeat region epitopes in immune sera. The
 .circumsporozoite protein CS protein of Pf contains
tandem repeats of the sequence NANP and the vari-
w xant sequence NVDP 99 . Almost all the reactivity
Table 1
Parasite stage Immunological mechanism Ref.
w x1. Sporozoite Antibody mediated inhibition of invasion of hepatocytes and parasite development 72,73
w xC reactive protein and complement fixation 74
q q w x2. Infected hepatocytes CD8 and CD4 cytotoxic lymphocytes kill infected hepatocytes directly 75,76
w xAntibody dependent cell mediated cytotoxicity 77
w xIndirect killing of infected hepatocytes via cytokines, etc. released by T cells 58,78,79
and activated macrophages
w x3. Asexual blood stages Agglutination of merozoites 80,81
w xBlocking rbc recognition 82,83
w xComplement mediated lysis of merozoites 47
w xAntibody dependent killing by neutrophils 56
w xAntibody dependent killing by monocytesrmacrophages 84,85
w xKilling by activated macrophage derived cytokines, 86–89
reactive oxygen and nitric oxide derivatives
 . w xNatural killer NK cell mediated cytotoxicity 90
w xReversal of cytoadherence 91
w xAntibodies neutralising parasite toxins 52,53,92
4. Sexual stages Transmission to mosquito blocked by antibodies to
 . w xi gametes 93
 . w xii zygoterookinete 94
 . w xiii mosquito midgut 95
w xTNF mediated inactivation of gametocytes 96
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against the CS protein in immune sera from endemic
areas was reportedly directed against the repetitive
w xepitope 100 . This indicates the immunodominant
nature of the repeat region. A more recent study
however shows that the conserved repeat region may
be less immunodominant in areas of lower endemic-
w xity 101 . Natural antibodies to a heat stable protein
found in the parasitophorous vacuole that is released
 .during schizogony termed the S-antigen and a pro-
tein located on the inside surface of the rbc mem-
brane in association with spectrin termed ring ery-
.throcyte surface antigen or RESA also react pre-
dominantly with repetitive epitopes on the proteins
w x102 .
Repeats are seen in many parasite proteins found
in different sub-cellular locations and probably serv-
ing quite different functions. Apart from the exam-
ples discussed above, repeats are found in a 200 kDa
protein localised in the parasitophorous vacuole of
w xliver stage parasites termed LSA-1 103 , MSA-1
w x w x40 , MSA-2 41–43 , proteins associated with the rbc
membrane knobs e.g. the knob associated histidine
w xrich protein or KAHRP 104 , and a protein present in
the rhoptry–microneme complex of the parasite
termed the rhoptry associated protein 1 or RAP-1
w x105 . On the other hand, several Pf proteins includ-
w xing structural proteins, e.g. actin 106 and tubulin
w x107 , rhoptry–microneme proteins, e.g. the apical
w xmerozoite antigen or AMA-1 108 , and enzymes,
e.g. hypoxanthine-guanine phosphoribosyl transferase
w x w x109 and aldolase 110 , lack tandem repeats.
7.2. Structural features of Pf repeats
The size of repeats in Pf proteins is quite variable.
w xThe clustered asparagine rich protein or CARP 111
contains long tracts of asparagine, while the serine
rich antigen or SERA is composed of 11% serine
w xpresent in polyserine tracts 112 . KAHRP and other
histidine rich proteins of the parasite contain blocks
w xof histidine 104 . Two allelic families of MSA2 are
w x w xobserved in laboratory 43 and field 113 isolates
consisting of either 4–8 a.a. repeats rich in S,G and
A or a 32 amino acid repeat and a ESNSRSPPITTT
sequence repeated several times. A protein termed the
glycophorin binding protein or GBP has multiple
w xrepeats of a 50 a.a. sequence 114 . Different allelic
forms of some Pf molecules can possess repeat units
of greatly varying sizes, e.g. in MSA-2. In two
S-antigens there is underlying homology in the DNA
sequences that produce different repetitive sequences
w xthat do not cross-react antigenically 115 . This sug-
gests that these S-antigen repeats may have evolved
from a common ancestral gene sequence. In contrast,
the two known nonapeptide repeats of the CS protein
of P˝ show no homology at the DNA level and
w xtherefore could have evolved independently 116 .
X The 11 a.a. repeat at the 5 end of RESA sequence
.DDEHVEEPTVA and the eight and four amino acid
X repeats in the 3 end sequences of EENVEHDA and
. w xEENV are conserved among all known isolates 117 .
Repeats within a particular region of a protein are
often not exact, degeneracy being particularly evident
towards the ends of each region. The genetic mecha-
nisms for maintaining the repeats and for generating
new repeat sequences are not known, but processes
such as gene conversion, replication slippage and
unequal crossing over are probably important. Im-
mune pressure has been suggested to drive the forma-
tion of variant repeat sequences within a given pro-
 .tein discussed in Section 9 .
A comparison of the a.a. composition of the re-
peats containing fourteen or fewer amino acids and
the non-repeat region of several Pf proteins shows
w xsignificant differences 118 . Most marked is the
paucity of cysteine and the hydrophobic amino acids
Y, W, F, M, L and I in repeats. Analyses of ten
individual antigens show that the repeats are more
hydrophillic than the corresponding non-repeat re-
w xgions of the proteins 118 . The difference between
the repeat and non-repeat regions is less evident
when large repeats G32 a.a. are used for comparison
w x118 . This may reflect a different role for the large
repeats in parasite proteins. Chou–Fasman analysis
of the secondary structure of the shorter repeats
predicts that these probably assume a beta turn con-
w xformation 118 . Indeed circular dichroism studies
 .indicate that the NANP repeat of the Pf CSn
 .protein and the GQPQAQGDGANA repeat of then
P. knowlesi CS protein assume a reverse turn confor-
w xmation in solution 119 . The amino acid composition
and hydrophilicity of the repeats are also consistent
w xwith the formation of surface loops 120 . Loops and
beta turns on the surface of proteins generally exhibit
considerable atomic or segmental mobility and there
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is a good correlation between such structures and the
w xlocation of B cell epitopes in many proteins 121 .
7.3. Possible functions of repeats in immune e˝asion
The presence of extensive repeats in many Pf
proteins suggests a functional role for the repeats. It
is possible that the repeats act as receptors or ligands
for host proteins, with high affinity of interaction
being generated through multivalent binding. Ini-
tially, this hypothesis was supported by an observa-
tion that the binding affinity of recombinant GBP to
glycophorin is directly related to the number of re-
w xpeats 114 . It was therefore thought possible that the
GBP repeats have a function in the recognition of rbc
w xby merozoites 114 . More recent work suggests that
GBP is secreted into the rbc cytoplasm by mature
parasites and that, while it may bind to intracellular
domains of glycophorin, it does not play a role in rbc
w xrecognition by merozoites 122 . Repeat-host
molecule interactions with a definite function have
therefore not been unequivocally identified yet for Pf
proteins. On the other hand there is evidence that
repeats function to nullify a protective host immune
response in different ways and some possible mecha-
nisms are described below.
7.3.1. Antigenic di˝ersity in repeats
Since repetitive sequences constitute immunodom-
inant epitopes in parasite proteins, sequence variation
in allelic forms of the molecules may prevent the
population developing immunity to different strains
of the parasite. The Pf S-antigen shows extreme
diversity in repeat sequences and may provide an
example. This is discussed in detail in Section 9.2.
7.3.2. Cross reactions between repeats interfere with
affinity maturation of the antibody response
The use of immune sera and synthetic peptides
demonstrates cross-reactivity between two forms of
the eight amino acid repeats of the NF7 isolate
S-antigen that differ in the use of R or L in one
w xposition 102 . Similarly immune sera and mono-
 .clonal antibodies mabs demonstrate cross-reactivity
between the EENV and EENVEHDA repeats at the 3X
end of RESA and between EENV and the 5X repeat of
w xDDEHVEEPTVA 102 . Cross-reactions are also seen
between epitopes in repeat regions and epitopes in
non-repetitive regions of other proteins. Sequences
recognised by an IgM mab that reacted with MSA-2,
RESA, the FC27 isolate S-antigen and another asex-
ual stage antigen composed of dispersed blocks of
hexapeptide repeats with the consensus sequence
PVTTQE the falciparum interspersed repeat antigen
w x. w xor FIRA 123 have been analysed 124 . This was
done by reacting the mab with sequentially overlap-
w xping peptides from MSA-2 and FIRA 124 . The
optimal epitope on MSA-2 had the tetrapeptide se-
quence STNS but a replacement net analysis revealed
that a surprising degree of substitution was tolerated
w xin each of the four positions 124 . The sequence
STNS is found in the 32 a.a. repeat of the FC27
MSA-2 protein. The strongest mab binding peptides
in FIRA were not found in the repeat but in other
w xsequences that were rich in S, T and N 124 . Simi-
larly, asparagine rich epitopes are reported to mediate
the extensive cross-reactions, observed using poly-
clonal sera, between ten different asexual stage anti-
 .gens and the NANP epitope on the Pf CS proteinn
w x125 . Normal affinity maturation of the antibody
response depends on the preferential binding of the
declining numbers of antigen molecules with B cells
whose antigen receptors have undergone somatic mu-
tation in the V region to produce receptors with
greater affinity for the antigen. This process takes
place in the germinal centres of lymphoid organs. B
cell blasts that are not selected in this manner in the
germinal centres undergo apoptosis while the selected
higher affinity cells differentiate into antibody secret-
ing plasma cells or B memory cells. Isotype switch-
ing also occurs in the germinal centres under the
influence of T cell derived cytokines. It has been
argued that the presence of large amounts of antigens
containing cross-reactive epitopes will allow contin-
ued stimulation of low affinity cells in germinal
w xcentres 102 . Since there is a limit to the numbers of
B cells that can mature, imposed by physical con-
straints of the lymphoid organ, cytokine availability,
etc., this effectively results in hypergammaglobuli-
naemia with a reduced proportion of high affinity
antibodies and impaired isotype switching.
7.3.3. Repeats as B cell superantigens
A related possibility, for which there is at present
no direct experimental evidence, is that the parasite
repeats may bind to either framework Fv determi-
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nants or the Fc portion of B cell antigen receptors
thereby cross linking them and causing polyclonal B
cell activation. Such a property would be analogous
to retroviral proteins and bacterial exotoxins that act
w xas T cell superantigens 126 . Consistent with this
mechanism, polyclonal B cell activation, measured in
terms of increased numbers of IgM, IgA and IgG
secreting cells and higher levels of the corresponding
w ximmunoglobulins, has been reported in malaria 60 .
The changes were more marked for falciparum than
vivax malaria, and all the parameters tended to return
w xto normal levels 15–30 days after chemotherapy 60 .
7.3.4. Generation of a T-independent antibody
response by repeats
Sporozoite immunisation experiments in mice that
 .show that the antibody response to the NANP n
repeats of the Pf CS protein is a T-independent one
w x127 . This is in contrast to the response to synthetic
 .NANP peptides where T dependence has beenn
extensively documented. Pf proteins containing re-
peats may function as type 2 thymus independent
antigens that are typically able to persist on
macrophage surfaces and bind multivalently and
cross-link antigen receptors on repeat-specific B cells.
Pf proteins containing repeats may also have an
element of type 1 thymus independent antigen activ-
ity. A parasite derived mitogenic activity, which may
w xpermit this, has been described 128 . T-independent
antibody responses are usually short lived, predomi-
nantly composed of IgM and IgG3 and of low affin-
ity. There is evidence to suggest that IgM dominates
the natural antibody response to the Pf CS repeat in
w xendemic areas 129 . Natural IgG antibody responses
to MSA-2 in The Gambia are predominantly of the
IgG3 subclass and directed principally towards the
w xrepetitive region 130 . Not all the repeat regions of
different proteins however contain the extensive re-
peats seen in the CS protein, RESA, S-antigen or
FIRA. If 12–16 haptenic groups are necessary for
cross-linking B cell antigen receptors for a type 2
w xT-independent response 131 , this condition is not
met with in several proteins containing repeats e.g.
MSA-1 and MSA-2. However immune complexes
presented on the surface of antigen-presenting follicu-
lar dendritic cells may provide the required epitope
density for such antigens to stimulate a T-indepen-
dent antibody response.
7.3.5. Cross reacting repeat epitopes as an antibody
sink
Another hypothesis regarding the role of repeats in
immune evasion is based on the properties of surface
location, segmental mobility and multimericity dis-
cussed in Section 7.2. Many proteins containing ex-
tensive repetitive regions, such as FIRA and the
S-antigen, are present in relatively large amounts in
schizonts and are released during schizont rupture. It
has been suggested that they may, because of their
inherent cross-reactivity with epitopes on functionally
important merozoite proteins, serve to mop up anti-
bodies that might otherwise bind to merozoites in the
w xvicinity and prevent invasion 124 . Such a scenario
may be particularly relevant in the microenvironment
of a rosette of rbc surrounding a cytoadherent irbc in
Pf infections.
The diverse mechanisms of immune evasion in-
volving repeats discussed here are not mutually ex-
clusive. Different repeats may generate different im-
mune evasion mechanisms and it is possible that
some repeats may have non-immunological functions
such as binding to host receptors. Elucidation of V
gene usage and somatic mutation patterns, histology
of the germinal centres, conformation of repeats, the
isotypes of natural antibodies to different repeats, and
further characterisation of mitogenic activity in
malaria may help to clarify some of the mechanisms
discussed here.
8. Molecular mimicry and immune evasion
Many parasites mimic host molecules to avoid
immunity. Schistosomes, which live in blood vessels
of the host, readily absorb host serum components
onto their surface thereby reducing immunogenicity.
An analogous phenomenon has not been reported in
malaria. Transforming viruses produce proteins, e.g.
the SV40 T antigen, that interfere with cell cycle
control in permissive host cells by mimicking the
functions of certain host proteins. The sequences of
two Pf proteins, termed Ag332 and Ag11-1, show
sequence homology to a -thymosin, a thymic peptide1
hormone that modulates differentiation of T cells.
Synthetic peptides based on the two Pf proteins had
similar biological effects to the hormone on T cells
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w x132 , and this may interfere with development of
protective immunity in malaria.
9. Antigenic diversity as a mechanism of avoiding
host immunity
Antigenic diversity for the purpose of this discus-
sion is termed to be the existence of different allelic
forms of parasite proteins. Since the parasite is hap-
loid in man, only one allele per locus is expressed in
the blood stages. The presence of ˝ar genes coding
for the 200–300 kDa Pf EMP-1 protein on the rbc
surface in multiple loci and the ability of the parasite
to switch expression between different loci in the
w xasexual blood stage 14–16 is termed antigenic vari-
ation and is discussed separately in Section 10. Se-
quence diversities in housekeeping genes of the para-
site are probably no greater than that seen in the
corresponding host proteins. The enzyme dihydrofo-
 .late reductase-thymidylate synthase DHFR-TS is
probably the most extensively studied parasite house-
w xkeeping gene 133 . The sequences of DHFR-TS in
different isolates of Pf are almost identical except for
changes in the active site of the enzyme that generate
resistance to the anti-folate drugs pyrimethamine and
w xproguanil 133 . The situation in parasite antigens that
play a role in host immunity is quite different. Using
panels of mabs, extensive antigenic polymorphism
w x w xhas been shown in Pf 134 and P˝ 135 . The basis
for this polymorphism is the existence of multiple
 w x.allelic forms of many proteins reviewed in 136
that have markedly different B cell epitopes. Recipro-
cal recombination within particular genes, that pro-
duce different combinations of B cell epitopes, adds
w xto the diversity 136 . Furthermore within particular
allelic forms there occur more restricted sequence
changes such as point mutations which may give rise
to further diversity in B cell epitopes and generate
different T cell epitopes. Diversity in B cell epitopes
is driven by antibodies. On the other hand diversity in
T cell epitopes is more complex and involves selec-
tion during proteolytic processing, binding to MHC
class I or II molecules, and recognition by T cell
receptors. The structural nature and immunological
significance of the diversity are best illustrated by
considering three proteins in greater detail, viz. the
CS protein, the S antigen and MSA-2.
9.1. CS proteins
The CS protein is the major constituent of the
outer coat of the sporozoite. CS proteins from differ-
ent Plasmodia show the same basic structure com-
posed of a single central domain of extensive repeats
 .Fig. 2 . Sequences that are relatively conserved be-
tween different species are found immediately to the
N-terminus of the repeats and towards the C-terminus
of the protein. Sequences in the conserved regions are
w xreportedly involved in hepatocyte recognition 137 .
The Pf CS repeat in all isolates is composed of the
sequence NANP and the variant sequence NVDP.
The Pf 7G8 isolate for example contains 37=NANP
w x  .and 4=NVDP repeats 99 Fig. 2 . Two different
alleles of the CS repeat are found in P˝, being
com posed of the nonapeptide sequences
 . .  .ANGA GrD NrD QPG and DRA DrA GQPAG
w x138 . An analysis of the frequency of occurrence of
single nucleotide substitutions producing synony-
 .  .mous d and non-synonymous d a.a. changes ins n
the Pf CS protein showed significantly greater non-
synonymous changes in the region C-terminal to the
repeats that is also known to harbour identified Tc
w xand T cell epitopes 139,140 . Furthermore, thish
analysis showed that the non-synonymous changes in
the C-terminus were more likely to be radical ones
i.e. involving a change between the categories of
 . positively charged H, R, K , negatively charged D,
.  .E or neutral all other amino acids. Analysis of the
T epitopes of P˝ however produced conflicting data
as to the significance of greater-non-synonymous a.a.
w xchanges 138,140 . Rodent malaria parasites on the
other hand showed no greater d compared to dn s
changes in the sequences containing known T epi-
w xtopes 139 . It is possible that this is due to the fewer
rodent CS protein sequences analysed. The relative
 .Fig. 2. Structure of the Plasmodium falciparum 7G8 isolate and
 .  .P. ˝i˝ax Belem isolate circumsporozoite CS proteins. The
alternative repeat found in P. ˝i˝ax strains is
 . .ANGA GrD NrD QPG.
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Fig. 3.
Serotype Repeats
 .  .3D7 57=ED ErK VSNG RrG
HB3 80=ETGPGKAGEQG
Wellcome 65=GPNSDGDK
 .KF1917 78=GDQTEGS SrA GGK
 .NF7 43=A RrL KSDEAE
K1 22=GSDQEVKVQKEQ
V1 19=GGPGSEGPKGT
 .KF1916 100=AGSNE ErK
FC27 100=PAKASQGGLED
Structure of the S antigens with the sequences of the central
repeats that determine the serotype. L – leader sequence; A –
flanking region of limited variability; B – a non-repetitive se-
quence of 10–12 a.a. present in some proteins; C – a region
present in some proteins that may consist of 15mer repeats; D – a
w xregion of limited variability 115 .
conservation of the central repeat but variation in the
T epitope regions is consistent with accumulating
evidence that antibodies against the repeats are pro-
tective only at high concentrations that are not fre-
w xquently seen in endemic areas 141 , and that T cell
dependent immune responses directed against in-
fected hepatocytes which may also express CS pro-
.tein derived peptides on the surface are important for
w ximmunity 141,142 .
9.2. S-antigens
The S-antigen is a heat stable protein secreted into
w xthe parasitophorous vacuole 115 . It is released in
copious amounts during schizont rupture and shows
 .extreme size polymorphism 50–220 kDa and sero-
w xlogical diversity 115 . The function of the protein is
unknown. Although a mab against the FC27 repeat
reportedly inhibits parasite growth in vitro, there is
no other definitive evidence as to its role in immune
w xprotection 143 . Nine S antigens have been charac-
terised that differ in the sequence of up to 100 repeats
w x  .in a centrally located domain 115 Fig. 3 . The
sequence of the repeats determines the serotype of
the protein, since human antibodies are directed pri-
w xmarily against epitopes in the repetitive region 102 .
It is reported that over 50 serotypes may be prevalent
w xin endemic areas 115 . However, the N- and C-
terminal flanking regions are composed of a few
defined and relatively conserved sequences. Analysis
of the flanking regions for d and d showed thatn s
these were approximately equal, arguing against sig-
nificant immune pressure for variation in these re-
w xgions 140 . A similar analysis was not possible, or
indeed required, for the central repeat because of the
extreme variability. The rapid evolution of different
repeats in the S antigen, accompanied by relative
homogeneity of repeats within a particular molecule,
probably involves mechanisms such as unequal cross-
ing over, replication slippage and gene conversion.
The extreme diversity of the S antigen repeats is
good evidence for antibody driven selection. Support
for this theory is provided by observations that indi-
viduals infected with one serotype are unlikely to be
reinfected soon with the same serotype and that the
prevalence of a serotype in a village population varies
with time in a manner consistent with antibody driven
w xselection 144,145 .
9.3. MSA-2
The MSA-2 protein is an integral membrane pro-
tein on the merozoite surface and mabs to the protein
w xcan inhibit parasite growth in cultures 41,42,82 .
Two allelic families of MSA-2 are present in labora-
w xtory and field isolates 43,113 . These differ chiefly
in a central region containing repetitive sequences
and flanking non-repetitive sequences, while the N-
terminal 42 a.a. and the C-terminal 75 a.a. are con-
 .served between alleles Fig. 4 . Within each family
w xoccur sub-families 43,146 . Limited recombination is
observed between different alleles even within the
w xcentral variable region 147 . Natural antibody re-
sponses are directed principally against the variable
Fig. 4. Structure of two MSA-2 proteins from Sri Lanka. D2 and
P2 belong to the two major allelic families represented by the
w x  .K1rFC27 and 3D7 isolates respectively 113 . Conserved black ,
 .allele-specific flanking striped or stippled and the repeat regions
in the two molecules are indicated.
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w xregion of MSA-2 130 but reactivity is also seen
towards a peptide in the conserved C-terminus when
w xa sensitive radioimmunoassay is employed 148,149 .
Analysis of synonymous and non-synonymous muta-
tions in MSA-2 revealed significantly higher non-
synonymous changes in the N-terminus, but not in
the more membrane proximal C-terminus, both within
w xand between the two allelic families 140 . These
changes, and the more obvious differences between
the alleles in the repetitive region, are likely to be
driven by selection pressure exerted by both antibod-
 .ies and T cells. The D2 Fig. 4 or FC27rK1 like
allele is more commonly found in parasites isolated
w xfrom patients 150,151 and is significantly more
w xfrequent in persons with symptomatic malaria 152 .
The data therefore suggests that this allelic type may
be more virulent.
Analyses, similar to those presented above for the
CS protein, the S-antigen and MSA-2, showed that
non-synonymous changes were significantly more
frequent in some regions of genes coding for MSA-1
w x w x153 , the extracellular region of AMA-I 140,154
and all regions of a minor component of the sporo-
zoite surface termed TRAP thrombospondin related
w x. w xanonymous protein, Ref. 155 140 . Indeed two
peptides independently shown to be T cell epitopes in
w xMSA-1 156 were located in a region where d )dn s
w x140 . On the other hand d and d were approxi-n s
mately equal in the liver stage antigen LSA-1, the
knob associated histidine rich protein KAHRP and, as
described in Section 9.2, the S-antigen regions flank-
w xing the repeats 140 . The latter group of
proteinsrprotein segments appear to be be evolving
neutrally like pseudogenes i.e. without strong selec-
tion pressure either for conservation of sequence as in
most house keeping proteins, or epitope diversifica-
tion as with sporozoite and merozoite surface pro-
teins.
A common explanation advanced for the age re-
w xlated change in clinical immunity to malaria 69 is
that such protection requires significant immunity
against conserved epitopes or a pool of common
variant epitopes and that this in turn requires multiple
exposure to infections. Antibodies to conserved epi-
topes on critical antigens, e.g. the 19 kDa C-terminus
w xof MSA-1 83,157 , are indeed associated with pro-
tection against falciparum malaria. Since such anti-
w xbodies are generally short lived 129,148–150,158 ,
long term immunity in the absence of continuous
reinfection, according to this theory, requires the
development of sufficient numbers of high affinity B
and T memory cells against critical epitopes on rele-
vant parasite proteins.
10. Antigenic variation as a mechanism for
evading host immunity
The location of asexual blood stages except mero-
.zoites and gametocytes of Pf inside the rbc shields
them from damage mediated by antibodies directed
against the vast majority of parasite molecules. Mero-
 .zoites and sporozoites are exposed to antibodies for
only a very short time before they invade target cells.
Mature rbc do not express MHC molecules on their
surface that are needed for recognition by cytotoxic T
cells. Antigenic parasite derived molecules exposed
on the rbc surface are however accessible to antibod-
ies for relatively long periods. This is unfavourable to
the parasite and would be selected against unless
such molecules perform essential functions e.g. trans-
port, or confer other advantages e.g. sequestration in
capillaries. An antigenically variable surface antigen
on the surface of irbc was first demonstrated in the
w xmonkey malaria parasite P. knowlesi 159 . The anti-
gen was termed the schizont infected cell agglutinin
or SICA since homologous antibodies agglutinated
the irbc. The corresponding antigen identified later in
w xPf contained conserved and variable epitopes 160 .
Consistent with one theory of age related develop-
w xFig. 5. Structure of the ˝ar gene products 15 .
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ment of immunity to malaria, children predominantly
possessed antibodies to variable epitopes while adult
sera showed greater reactivity with conserved epi-
w xtopes on Pf SICA 160 . The SICA molecule under-
goes rapid clonal variation in antigenicity without
immune pressure in cultures estimated at 2% per
.generation , with concurrent alterations in cytoadher-
w xence and rosetting characteristics 161 . The antigenic
variation was associated with a large protein previ-
ously identified by radiolabelling of Pf irbc as
w xPf EMP-1 162,163 . Although altered rbc compo-
w x w xnents 17,18 and rosettins 25 may have a role in
adherence of irbc, these molecules do not display the
antigenic variability that is characteristic of Pf EMP-
1. Genes for Pf EMP-1 have now been characterised
w xand termed the ˝ar genes 14–16 . Var genes are
present on different chromosomes and an estimated
50–150 genes code a family of 200–350 kDa
Pf EMP-1 molecules that are predominantly located
in the knobs on irbc. Expression of distinct var gene
transcripts correlates with the synthesis of specific
w xsurface antigens on the irbc 16 . More than one var
gene can be expressed in a parasite clone. Although
the sequences of different Pf EMP-1 molecules are
very variable, they contain certain common features
 .Fig. 5 . One to four cysteine-rich domains homolo-
gous to regions found in the P˝ merozoite ligand for
w xDuffy blood group antigens 164 and the Pf mero-
w xzoite ligand for glycophorin A 165 are present in
Pf EMP-1 and these are termed Duffy binding like or
DBL domains. The first domain near the N-terminus
 .DBL-D1 is the most conserved of the DBL do-
mains. Between DBL-D1 and DBL-D2 is a relatively
 .conserved cysteine rich inter domain region CIDR
of 300–400 a.a. The relatively conserved nature of
DBL-D1 and the CIDR at the N-terminus is consis-
tent with a conserved function for the different
Pf EMP-1 molecules. The numbers and location of
the other DBL domains are more variable. A hy-
 .drophobic transmembrane segment TM is encoded
in the 3X end of the first exon and this is followed by
a 45–55 kDa putative cytoplasmic acidic terminal
 .segment ATS coded for by a second exon. A N-
terminal signal sequence is absent from the deduced
protein sequence of PfEMP-1.
It is speculated that conserved motifs in the DBL
and CIDR domains maintain the conformation of the
protein required for ligand binding and that the sur-
rounding variable regions may be more exposed to
antibodies and provide the basis for immune evasion
w x15 . Variations in the numbers and location of DBL
domains D2 to D4 may govern the specificity of
wbinding to the different cytoadherence receptors 8–
x13 . In an analogous manner to trypanosome variant
w xsurface antigens 166 , different Pf EMP-1 molecules,
despite extensive sequence variation, may retain a
similar conformation that could be required for their
function. Genomic rearrangements of the type seen in
antigenic variation in trypanosomes are not essential
for the expression of ˝ar genes and the mechanism
of control of expression is yet to be determined.
11. Conclusions
Falciparum malaria has exerted significant selec-
tion pressure on human populations at the level of
w xhaemoglobin 167 and possibly major histocompati-
w xbility antigens 70 . Plasmodium is an ancient genus
and malaria parasites are also reported to have influ-
enced primate evolution 17–25 million years ago
w x47 . Such strong selection pressure implies that Pf
malaria causes high mortality in untreated individuals
w xand this is amply supported by existing evidence 2 .
Semi-immunity to the disease only develops in those
persons who survive the stringent selection process
that normally occurs in endemic areas during child-
hood. The availability more recently of anti-malarial
drugs, even in remote endemic areas, has however
somewhat changed this classical epidemiological pic-
ture. It is not clear at this time what causes the
semi-immunity which is almost never sterilising im-
.munity observed in adult endemic area populations.
Some possibilities are the acquisition of sufficient
numbers of high affinity memory B and T cells
against critical epitopes on parasite proteins, age and
infection related changes in the lymphoid organs and
down-regulation of the responses to cytokines medi-
ating malaria pathology. These mechanisms are not
mutually exclusive, and some changes may reduce
fitness and render the individual, who is semi-im-
mune to malaria, more susceptible to other infections.
They therefore require further investigation.
Extensive resources have been devoted to produc-
ing a synthetic malaria vaccine in recent years. In
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view of the complex and apparently effective im-
mune-evasion mechanisms evolved by malaria para-
sites, and the semi-immunity observed in endemic
area populations, it probably reasonable to ask the
question whether the induction of sterile immunity
against malaria is a realistic goal. Without a proper
understanding of the causes and other effects of
semi-immunity, sterilising immunity is perhaps the
most desirable outcome of vaccinating against
malaria. Immunisation with x-irradiated sporozoites
of Pf and P˝ is the one instance where sterilising
immunity to malaria, although short lived, has been
w xelicited in man 168 . Since using x-irradiated sporo-
zoites is not practical for mass vaccination, attempts
have been made to develop synthetic peptides, re-
combinant proteins, recombinant viral and bacterial
vectors and DNA vaccines based on sporozoite and
liver stage antigens for immunisation. The most
promising synthetic sporozoite vaccine to date con-
tains a part of the Pf 3D7 isolate CS protein fused to
 .hepatitis B surface antigen HBsAg produced and
assembled into particles containing non-recombinant
HBsAg in yeast. The particles when injected three
times into volunteers, with an adjuvant composed of
monophosphoryl lipid A and a saponin, gave an
estimated protection efficiency of 86% against chal-
w xlenge with 3D7 Pf sporozoites 169 . Monophospho-
ryl lipid A plus alum was less effective as an adju-
w xvant in this clinical trial 169 . The stronger adjuvant
that yielded the best protection in this study was
reported to be well tolerated in vaccinees, but more
detailed studies on its safety, and the protection
afforded against other Pf isolates by the vaccine, are
warranted before field use. Sterilising immunity
against Pf blood stages has been reported in Aotus
monkeys after immunisation with asexual stage para-
w xsites in Freunds adjuvant 170 , but similar results
have not been achieved with synthetic asexual stage
vaccines incorporating adjuvants acceptable for hu-
man vaccination. It is possible that significant levels
of proinflamatory cytokines are essential for develop-
ing sterile immunity. This may be simulated, for
example, by injecting IL-12 which has been shown to
protect rhesus monkeys against P. cyanomolgi sporo-
w xzoites 171 . Malaria, and vaccination against malaria,
may therefore illustrate a tenuous divide between
protective immunity and pathogenicity in the human
immune response.
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